Catalyst Event
ABL Bio Inc (298380) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/17/2026, 12:00:00 AM
Partner NovaBridge Biosciences confirmed a potential accelerated approval pathway for gastric cancer treatment Givastomig (ABL111) following a Type B meeting with the U.S. FDA on March 17, 2026. This regulatory milestone for a lead asset is estimated to have a high market impact.
Korean Translation
파트너사 노바브릿지 바이오사이언스가 2026년 3월 17일 미국 FDA와의 B타입 미팅을 통해 위암 치료제 기바스토믹(ABL111)의 가속 승인 가능성을 확인함. 주요 파이프라인의 규제적 성과로 높은 시장 영향력이 예상됨.
Related Recent Events
Daewoong Pharmaceutical Co Ltd (069620) · Other
The Annual General Meeting of Shareholders is scheduled for March 26, 2026, to re-appoint CEO Park Sung-su and add new business purposes; analysts estimate these routine governance matters will result in a 1-5% price impact scheduled.
3/26/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
The 15th Annual General Meeting of Shareholders including CEO re-appointment on March 26, 2026 scheduled.
3/26/2026, 12:00:00 AM
Alteogen Inc (196170) · Other
The second-largest shareholder, holding a 5.05% stake, announced on March 19, 2026, their intention to vote against the re-election of the CFO at the upcoming general meeting, citing a lack of shareholder-friendly policies; a 5-10% price impact is expected.
3/19/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
A conflict with the Korea Pharmaceutical Distribution Association escalated around March 18, 2026, over a new 'hub wholesaler' policy; analysts estimate the potential boycott and sales disruption will cause a price impact of 5% or more expected.
3/18/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
Joint venture Mentis Care to begin joint research with Emory University on March 17, 2026, for AI-based seizure detection expected.
3/17/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a plan for a record-high cash dividend of 2,000 KRW per common share to be approved at the March 31, 2026 AGM; medium importance due to positive impact on shareholder value, scheduled.
3/16/2026, 12:00:00 AM